Close Menu


Tekmira Pharmaceuticals said this week that it has begun enrolling patients in a phase I trial of its Ebola virus infection treatment TKM-Ebola.

Tekmira Pharmaceuticals this week announced that it has received clearance from the US Food and Drug Administration to begin human testing of an RNAi-based treatment for Ebola virus infection.

Tekmira officials said that under the Ebola contract, the company has been able to scale up its lipid nanoparticle technology to support late clinical development and therapeutic manufacturing.

By combining new viral transduction findings with existing gene expression data for more than 50 human cell lines, researchers have identified a cell surface receptor that seems to mediate cellular entry for Zaire ebolavirus and Lake Victoria Marburgvirus.

Under the deal, Alnylam stands to receive royalties on sales of products developed using the licensed technology. Additional terms were not disclosed.

According to the company, the grant will support the use of its lipid nanoparticle delivery technology to develop the therapeutics.

The company also continues to make advances with its investigational cancer therapy and its bid to list its shares in the US, and said it expects "to be listed in Nasdaq in the next one to two months."


A tissue sample from the 1960s harbors a near-complete sample of HIV, IFLScience reports.

A new bill would reshape the US National Science Foundation to include a focus on technological development, according to Science.

The Food and Drug Administration's decision to halt a SARS-CoV-2 study has drawn criticism, according to Stat News.

In Genome Biology this week: features affecting gut microbiome and parasite patterns, cellular interactions in lung tumor microenvironment, and more.